Synthesis and antiproliferative activity of benzo[d]isothiazole hydrazones

European Journal of Medicinal Chemistry

Volumn 41, Issue 5, 2006, Pages 624-632

  Vicini, Paola ^a   Incerti, Matteo ^a   Doytchinova, Irini A ^b   La Colla, Paolo ^c   Busonera, Bernadetta ^c   Loddo, Roberta ^c  

^a UNIVERSITY OF PARMA   (Italy)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^c Cittadella Univ di Monserrato   (Italy)

Author keywords

Antiproliferative activity; Benzo d isothiazole hydrazones; Conformational analysis; Cytotoxicity; Synthesis

Indexed keywords

ANTIRETROVIRUS AGENT; BENZ[D]ISOTHIAZOLE HYDRAZONE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HYDRAZONE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG IDENTIFICATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; LEUKEMIA; LYMPHOCYTE; SOLID TUMOR; VIROGENESIS; CELL LINE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; SPECTROSCOPY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTINEOPLASTIC AGENTS; CELL LINE; CELL PROLIFERATION; HUMANS; HYDRAZONES; HYDROGEN BONDING; MOLECULAR STRUCTURE; SPECTRUM ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 33746672069     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2006.01.010     Document Type: Article

References (15)

1. Vicini P., Amoretti L., Tognolini M., Ballabeni V., and Barocelli E. Bioorg. Med. Chem. 8 (2000) 2355-2358
2. Vicini P., Fisicaro E., and Lugari M.T. Arch. Pharm. Pharm. Med. Chem. 333 (2000) 135-144
3. Vicini P., Zani F., Cozzini P., and Doytchinova I. Eur. J. Med. Chem. 37 (2002) 553-564
4. Zani F., Vicini P., and Incerti M. Eur. J. Med. Chem. 39 (2004) 135-140
5. Geronikaki A., Vicini P., Incerti M., and Hadjipavlou-Litina D. Arzneim.Forcsh/Drug Res. 9 (2004) 530-537
6. Vicini P., Geronikaki A., Incerti M., Busonera B., Poni G., Cabras C.A., and La Colla P. Bioorg. Med. Chem. 11 (2003) 4785-4789
7. Wermuth C.G. In: Wermuth C.G. (Ed). The Practice of Medicinal Chemistry (2003) 316-320
8. Resnati G. Tetrahedron 49 (1993) 9385-9445
9. Menozzi G., Merello L., Fossa P., Schenone S., Ranise A., Mosti L., et al. Bioorg. Med. Chem. 12 (2004) 5465-5483
10. Cao R., Peng W., Chen H., Hou X., Guan H., Chen Q., Ma Y., and Xu A. Eur. J. Med. Chem. 40 (2005) 249-257
11. Dias N., Jacquemard U., Baldeyrou B., Tardy C., Lansiaux A., Colson P., Tanious F., Wilson W.D., Routier S., Merour J., and Bailly C. Biochemistry 43 (2004) 15169-15178
12. Varvaresou A., Iakovou K., Gikas E., Fichtner I., Fiebig H.H., Kelland L.R., Double J.A., Bibby M.C., and Hendriks H.R. Anticancer Res. 24 (2004) 907-919
13. Brana M.F., Cacho M., Gradillas A., De Pascual-Teresa B., and Ramos A. Curr. Pharm. Des. 7 (2001) 1745-1780
14. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyster J., and De Clercq E. J. Virol. Methods 20 (1988) 309-321
15. Chem-X. 2000.1. Oxford Molecular Ltd. Chipping Norton, Oxfordshire OX7 5SR, UK.